European Patient Survey finds Crohn’s Disease Patients Living with Perianal Fistulas Experience a More Significant Negative Impact on Their Quality of Life than Crohn’s Disease Patients without Perianal Fistulas
The European Federation of Crohn’s and Ulcerative Colitis Associations(“EFCCA”) in collaboration with Takeda Pharmaceutical Company Limited(“Takeda”) today announced results from one of the largest of its kind self-reported patient surveys, exploring the health-related and overall real-world impact of perianal fistulas on the quality of life of people with Crohn’s disease (CD), compared to the impact of CD without perianal fistulas.1,2,3,4,5,6
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005192/en/
The survey found that CD patients living with perianal fistulas reported a more significant impact on their overall quality of life and an increase in certain symptoms, such as anal pain and perianal leaking, when compared to CD patients without perianal fistulas.1 CD patients living with perianal fistulas also reported feeling more unhygienic, uncomfortable, and guilty about their condition toward family and friends than CD patients without perianal fistulas.1
Perianal fistulas are a severe and disabling complication of Crohn’s disease,7 a chronic inflammatory disease that mainly affects the gastrointestinal tract and is associated with a substantial burden on the health-related quality of life of patients.8,9 In adult patients with CD, the cumulative incidence of perianal fistulas is estimated to be 15%, 21-23% and 26-28% over five, 10 and 20 years, respectively.10,11,12 Despite this, there have been few studies assessing the patient perspective of living with the condition.1
To understand the burden across many aspects of life, the survey explored topics across many areas. The findings show that as well as impacting work and social life, perianal fistulas had a greater negative impact on CD patients’ ability to do sports, work and employment, dating and sexual life.1 37.4% of CD patients with perianal fistulas stated that they were often unable to play sports, compared to 25.7% of CD patients without perianal fistulas.1 When asked about sexual activity, 26.4% of CD patients with perianal fistulas avoided having sex, 6.9% have ended relationships and 5.5% have avoided dating because of their painful condition.1 Almost double the number of CD patients with perianal fistulas compared to CD patients without perianal fistulas (14.3% vs. 8.0%) admitted they have had to change profession because of their condition.1 On top of this, the survey revealed that CD patients with perianal fistulas found it more difficult to talk about their condition with others, impacting their relationships.1
“We are proud to have embarked on this research to find out the impact of perianal fistulas on quality of life from patients’ perspective,” commented Luisa Avedano, Chief Executive Officer of EFCCA. “The results support what we have long suspected: that the added burden of perianal fistulas significantly impacts the lives of people with Crohn’s disease. The results will help us work to empower Crohn’s disease patients living with perianal fistulas and ultimately help to improve their lives.”
“We conducted this survey in order to obtain this greater understanding of the burden of living with perianal fistulas in addition to Crohn’s disease,” said Dana Agam, Patient Advocacy and Services Lead, GI Franchise Takeda Europe and Canada. “The findings of this survey may be useful in helping to tailor comprehensive care strategies to better support patients with this painful and disabling complication.”
About the International Patient Survey
There were 820 respondents to the anonymous, self-selective survey,1 making it one of the most comprehensive surveys on the patient perspective on life with perianal fistulas in Crohn’s disease to date.1,2,3,4,5,6 To ensure the results would provide valuable insights, the questionnaire was developed in cooperation with both medical and patient representatives.1 It consisted of 46 questions and assessed multiple aspects of living with CD, including topics such as impact on close relationships and social life, and impact on professional life.2 The survey itself which invited CD patients, with or without perianal fistulas to participate and self-select their diagnosis, was available through the EFCCA website from 15th July to 31st December 2019.1 Responses were received from 33 countries around the world, including countries in Europe, Colombia, Israel, Mexico, United States, Greenland, Dominican Republic and Guadeloupe.2 It was made available in English, French, German, Greek, Hebrew, Italian, Polish, Portuguese, Romanian, Spanish and Slovenian.2
The survey was commissioned and developed by EFCCA. Takeda provided editorial support in the development and distribution of the survey and analysis of data, and funded medical writing of the publication of results. The full survey findings are being presented at the virtual Congress of the European Crohn’s and Colitis Organisation (ECCO) taking place on 2nd – 3rd and 8th – 10th July, 2021.1
About Perianal Fistulas in CD
CD is a chronic inflammatory disease of the digestive system.13 People living with CD may experience perianal fistulas, which can cause intense pain, swelling, infection, and anal discharge.7,14 In adult patients with CD, the cumulative incidence of perianal fistulas is estimated to be 15%, 21-23% and 26-28% over five, 10 and 20 years, respectively.10,11,12 Perianal fistulas in CD are abnormal tracts with an internal opening in the anal canal or rectum and an external opening in the skin near the anus.15,16 They may develop from inflamed or infected anal glands and/or penetration of fissures or ulcers in the rectum or anal canal.15,16
European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA)
The European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) is an umbrella organization representing 45 national Crohn’s disease and ulcerative colitis (collectively known as inflammatory bowel disease or IBD) patient associations. We are an organization of people united in our commitment to improve the lives of the over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility. Our areas of intervention are networking, awareness raising, advocacy, empowerment, and solidarity. Our mission is to improve the lives of people with Crohn’s disease and ulcerative colitis. Our vision and ultimate goal are to find a cure for IBD.
Takeda in Gastroenterology
We believe that gastrointestinal (GI) and liver diseases are not just life-disrupting conditions, but diseases that can impact a patient’s quality of life.17,18 Beyond a fundamental need for effective treatment options, we understand that improving patients’ lives also depends on their needs being recognized. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides in addressing GI patient needs with treatments for inflammatory bowel disease (IBD), acid-related diseases, short bowel syndrome (SBS), and motility disorders. We are making significant strides toward closing the gap on new areas of unmet needs for patients who have celiac disease, eosinophilic esophagitis, alpha-1 antitrypsin-associated liver disease, and acute pancreatitis, among others. Together with researchers, patient groups and more, we are working to advance scientific research and clinical medicine in GI.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com/.
Spinelli A, Yanai H, Lönnfors S, et al. The impact of perianal fistula in Crohn’s disease on quality of life: results of a patient survey conducted in Europe. Presented virtually at ECCO, July 2021.
Spinelli A, Lönnfors S, Avedano L, et al. Patient perspective on the impact of complex perianal fistulas in Crohn’s disease on quality of life: Introducing the concept of the patient survey conducted in Europe. Poster P042 presented at ECCO 2020.
Panes J, Reinisch W, Rupniewska E, et al. Burden and outcomes for complex perianal fistulas in Crohn’s disease: Systematic review. World J Gastroenterol. 2018; 24 (42) 4821 – 4834.
Kasparek M, Glatzle J, Temeltcheva T, et al. Long-term quality of life in patients with Crohn’s disease and perianal fistulas: Influencer of Fecal Diversion. Diseases of Colon and Rectum. 2007; 50: 2067 – 2074.
Mahadev S, Young J, Selby W, et al. Quality of Life in Perianal Crohn’s disease: What do patients consider important? Diseases of Colon and Rectum. 2011; 54 (5): 579 – 585.
Adegbola S, Dibley L, Sahnan K, et al. Burden of disease and adaptation to life in patients with Crohn’s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. 2020; 18: 370.
Marzo M, Felice C, Pugliese D, et al. Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J Gastroenterol. 2015; 21(5): 1394-1395.
Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014 Jun 23;7:113-120.
Floyd, D.N., Langham, S., Séverac, H.C. et al. The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review. Dig Dis Sci. 2015; 60: 299–312.
Hellers G, Bergstrand O, Ewerth S and Holmstrӧm B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980; 21: 525-527.
Schwartz D, Loftus E, Tremaine W, et al. The Natural History of Fistulizing Crohn’s Disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-880.
Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn’s disease in a population based cohort. Dis Colon Rectum. 2012; 55(7): 773-7.
Xavier RJ and Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.
Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, et al. Management of complex perianal Crohn’s disease. Ann Gastroenterol. 2017; 30: 33-44.
Sandborn W, Fazio V, Feagan B, Hanauer S. AGA Technical review on perianal Crohn’s disease. Gastroenterology. 2003; 125 (5): 1508-1530.
Torkzad MR and Karlbom U. MRI for assessment of anal fistula. Insights Imaging. 2010; 1 (2) :62-71.
Center for Drug Evaluation and Research (CDER) & the FDA. The Voice of the patient/functional gastrointestinal disorder. 2016. Available at: https://www.fda.gov/media/95140/download. Last accessed July 2021.
Jones R, Hunt C, Stevens R, et al. Management of common gastrointestinal disorders: quality criteria based on patients’ views and practice guidelines. Br J Gen Pract. 2009; 59: e199-208.
Copyright 2021 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors27.10.2021 18:46:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005677/en/ “We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors. Collaborating with scientific innovators with unique technology platforms and deep domain expertise, such as the GammaDelt
FiRa Consortium Hits Major Milestones in Ultra-Wideband Momentum27.10.2021 18:00:00 CEST | Press release
The FiRa™ Consortium, a catalyst for bringing leading innovators together to drive Ultra-Wideband (UWB) expansion, is today announcing two milestones in the market acceptance of UWB technology. The first is the launch of the initial phase of its certification program aimed at driving interoperability between UWB devices. At the same time, FiRa Consortium is announcing it has now surpassed 100 members, including all of the top handset manufacturers globally, plus market leaders across semiconductors, networking, secure access, and consumer technology. “UWB is fast becoming a pillar of wireless local connectivity technology alongside Wi-Fi and Bluetooth,” said Charlie Zhang, Board Chair of FiRa Consortium. “When combined with the membership momentum we are seeing, our certification program signifies that the market is prepared and ready for broad implementation of UWB across market sectors.” FiRa Consortium’s certification program is the first to provide baseline testing and certificatio
Mitsubishi Corporation Life Sciences to Accelerate Next Wave of Digital Transformation and Business Growth by Switching to Rimini Street Support27.10.2021 18:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Mitsubishi Corporation Life Sciences, a food ingredients manufacturer within Mitsubishi Corporation’s Food Industry Group, has switched to Rimini Street Support for its JD Edwards applications. Switching from the vendor’s support to Rimini Street has enabled the company to dramatically reduce its maintenance costs and free up internal resources for strategic initiatives. By freeing up critical resources – time, money and personnel – Mitsubishi Corporation Life Sciences is able to begin investing in its digital transformation initiatives for the next five to 10 years and establish a foothold for further business expansion, both locally and overseas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005
CURACLE and Théa Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD27.10.2021 17:47:00 CEST | Press release
CURACLE, a Korea-based biopharmaceutical company, today announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation, the sister company of Théa, Europe’s number one independent ophthalmic company with a 150-year history, for the development and commercialization of CURACLE’s CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD). Under the terms of the agreement, CURACLE will receive an upfront payment of $6 million and could receive up to an additional $157.5 million in potential development, regulatory and sales milestones, as well as royalties on sales if CU06-RE is successfully developed, which will entitle CURACLE to receive up to $2 billion in total payments. Théa and CURACLE will closely collaborate on the clinical development of this novel oral drug. CURACLE will be responsible for the Phase I and II clinical studies with TOI
Everbridge Selected to Power the Nationwide Public Alert System for Spain27.10.2021 15:29:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM) and national Public Warning solutions, today announced the selection by Spain to deploy its next-generation population alerting technology to help keep the country’s more than 120 million residents and visitors safe and informed in case of an emergency. Everbridge announced the contract award anonymously in a press release last month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005638/en/ Everbridge Selected to Power the Nationwide Public Alert System for Spain (Graphic: Business Wire) The new country-wide public alert system of Spain will include both Cell Broadcast coverage at the national level, as well as the publication of alerts via the Web and through mobile alerts, powered by Everbridge. The state-of-the-art alert system will reach 99% of the population of Spain, including 47 million residents and nearly 80 million annual v
Earnix Again Recognized Among INSURTECH100’s Most Innovative Global Companies27.10.2021 15:23:00 CEST | Press release
Earnix, a global provider of advanced rating, pricing, and product personalization solutions for insurers and banks, has been again listed in INSURTECH100, recognizing the world’s most innovative InsurTech companies. Each year, a panel of industry experts and analysts led by FinTech Global, a data and research firm, evaluates hundreds of companies in the insurance industry for their business acumen, technological advancements and potential to make a lasting impact on the industry globally. “The insurance industry is going through a transformational period and Earnix is enabling insurers to seize the biggest opportunities and prevail in the face of challenges. With our unparalleled experience, operational efficiency, robust automation, and innovative analytics, we are helping carriers deliver decisions with agility via fully personalized dynamic insurance. We are pleased to be recognized again and will continue to innovate on behalf of insurers and their customers,” said Udi Ziv, CEO at
Airship Names Thomas Butta Chief Strategy and Marketing Officer27.10.2021 15:05:00 CEST | Press release
Airship, the mobile app experience company, today announced Thomas Butta has joined its executive leadership team as Chief Strategy and Marketing Officer, reporting directly to CEO and president Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005300/en/ SaaS branding expert and veteran CMO Thomas Butta joins Airship as Chief Strategy and Marketing Officer (Photo: Business Wire) Butta brings over two decades of marketing leadership and brand positioning expertise, resulting in billions of dollars of enterprise value created through market leadership, strategic acquisitions and record-breaking IPOs. Prior to joining Airship, Butta was CMO at SignalFx, and before that Sprinklr, where he redefined brand value around software observability and customer experience management respectively, resulting in SignalFx’s acquisition by Splunk and Sprinklr’s subsequent public offering under the ticker symbol, CXM (NASDAQ).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom